Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933353 | 0.79 | RAB9A (0.42) | ALOX15KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5605781 | 0.76 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1FFAR4 | |
| SCHEMBL5605161 | 0.76 | ALDH1A1 (0.41) | KMT2ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4672966 | 0.76 | PARP1 (0.42) | ALOX15KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7107412 | 0.76 | ALOX15 (0.49) | ALOX15KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5264923 | 0.76 | P2RX7 (0.43) | P2RX7ALOX15KMT2ANPC1RAB9A | |
| SCHEMBL3069181 | 0.76 | POLB (0.44) | ALOX15KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22924834 | 0.76 | KMT2A (0.44) | ALOX15KMT2AALDH1A1FFAR4PARP1 | |
| SCHEMBL13089951 | 0.75 | RAB9A (0.40) | KMT2ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4423238 | 0.75 | SYK (0.42) | ALOX15GRM5ALDH1A1FFAR4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135517-A1 | Imidazolopyridines and methods of making and using the same | BIOGEN IDEC MA INC. | 2006-06-22 | — | — | US | disclosed |
| EP-1546112-A4 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1546112-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004021989-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135517-A1 | Imidazolopyridines and methods of making and using the same | ALK, ACVR1, ACVRL1 | P2RX7 1955/4885ALOX15 2106/4885KMT2A 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.